Our Pipeline

Hummingbird Bioscience is developing antibodies against a number of important oncology and immuno-oncology targets where we believe there is an opportunity create significant impact. All programs are either first in class or have a highly differentiated mechanism that offers the potential for best in class efficacy.
Pipeline 2018


Recent Publications

Boyd-Kirkup, J. D., Thakkar, D., Paszkiewicz, K., & Ingram, P. J. (2018). Abstract 1729: Integrative immune profiling of syngeneic tumor models provides predictive immune signatures for treatment response with HMBD002, a novel anti-VISTA neutralizing antibody. Cancer Research, 78(13 Supplement), 1729–1729. https://doi.org/10.1158/1538-7445.am2018-1729


Ingram, P. J., Thakkar, D., & Boyd-Kirkup, J. D. (2017). Abstract 587: HMBD002, a novel neutralizing antibody targeting a specific epitope on the co-inhibitory immune checkpoint receptor VISTA, displays potent anti-tumor effects in pre-clinical models. Cancer Research, 77(13 Supplement), 587–587. https://doi.org/10.1158/1538-7445.AM2017-587


Boyd-Kirkup, J. D., Thakkar, D., & Ingram, P. J. (2017). Abstract 24: HMBD001, a novel anti-ErbB3 antibody with a unique mechanism of action, effectively inhibits tumor growth in pre-clinical models of ErbB3+ solid tumors. Cancer Research, 77(13 Supplement), 24–24. https://doi.org/10.1158/1538-7445.AM2017-24


Boyd-Kirkup, J., Thakkar, D., Brauer, P., Zhou, J., Chng, W.-J., & Ingram, P. J. (2017). HMBD004, a Novel Anti-CD47xCD33 Bispecific Antibody Displays Potent Anti-Tumor Effects in Pre-Clinical Models of AML. Blood, 130(Suppl 1). Retrieved from http://www.bloodjournal.org/content/130/Suppl_1/1378